Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | PRLHR | P49683 | 3/20 | 0.56 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.55 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.55 |
| ▸ | F11 | P03951 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.53 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152284 | 0.88 | PRLHR (0.63) | NPY2RPRLHRGLP1R | |
| SCHEMBL20003753 | 0.78 | PRLHR (0.58) | NPY2RPRLHRRXFP4RXFP3GLP1R | |
| SCHEMBL31277132 | 0.77 | KRAS (0.57) | NPY2RPRLHRCXCR4 | |
| SCHEMBL29365385 | 0.76 | KLKB1 (0.61) | — | |
| SCHEMBL23056722 | 0.75 | TEAD1 (0.53) | NPY2RPRLHRRXFP4RXFP3CXCR4 | |
| SCHEMBL27014090 | 0.75 | TEAD1 (0.53) | NPY2RPRLHRRXFP4RXFP3CXCR4 | |
| SCHEMBL20402542 | 0.75 | MC4R (0.53) | NPY2RRXFP4RXFP3CXCR4GLP1R | |
| SCHEMBL20003972 | 0.75 | MC4R (0.53) | NPY2RRXFP4RXFP3CXCR4GLP1R | |
| SCHEMBL29482473 | 0.74 | F11 (0.56) | PRLHRF11GLP1R | |
| SCHEMBL30883974 | 0.74 | KLK5 (0.55) | KLK5RXFP4RXFP3F11GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116870204-A | Self-limiting Auger electron medicine of coronavirus and preparation method and application thereof | 上海珺纳医疗科技有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20230184786-A1 | Methods of Detecting and Treating Immune Responses Associated with Viral Infection | FORSYTH DENTAL INFIRMARY FOR CHILDREN, d/b/a THE FORSYTH INSTITUTE | 2023-06-15 | — | — | US | claimed |
| WO-2023094571-A1 | STABILIZATION OF ACE2 FUSION PROTEINS | FORMYCON AG (DE) | 2023-06-01 | — | — | WO | claimed |
| US-20230149361-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS USING ANGIOTENSIN-CONVERTING ENZYME 2 INHIBITORS | Kumuda Inc. (US) | 2023-05-18 | — | — | US | claimed |
| US-20230111350-A1 | Opthalmic Compositions for Treating Coronaviruses | ZEBRA BIOTECH PTY LTD (AU) | 2023-04-13 | — | — | US | claimed |
| CN-112043838-B | ACE2 receptor targeted nuclide polypeptide probe, and preparation method and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-07-26 | — | — | CN | claimed |
| EP-4702027-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260053741-A1 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | COSMOSOFT (FR) | 2026-02-26 | — | — | US | disclosed |
| US-20260000618-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-04 | — | — | US | disclosed |
| WO-2022167526-A1 | METHOD FOR PROGNOSING THE COURSE OF A SARS-COV-2 INFECTION AND THE RESPONSE TO A SARS-COV-2 IMMUNIZATION AND/OR NATURAL INFECTION BY MEASURING SOLUBLE ACE2 | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| EP-4039818-A1 | METHOD FOR PROGNOSING THE COURSE OF A SARS-COV-2 INFECTION AND THE RESPONSE TO A SARS-COV-2 IMMUNIZATION AND/OR NATURAL INFECTION BY MEASURING SOLUBLE ACE2 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2022-08-10 | — | — | EP | disclosed |
| CN-112043838-B | ACE2 receptor targeted nuclide polypeptide probe, and preparation method and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-07-26 | — | — | CN | disclosed |
| CN-112043838-B | ACE2 receptor targeted nuclide polypeptide probe, and preparation method and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-07-26 | — | — | CN | disclosed |
| CN-112403309-B | High-precision proportioning material proportioning device for electroceramic processing | 江西铂川自动化科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3973794-A1 | FRAGRANCE-CONTAINING SHEET FOR HEATING-TYPE FLAVOR INHALER, AND HEATING-TYPE FLAVOR INHALER | Japan Tobacco Inc. (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022053993-A2 | TREATMENTS FOR SARS-COV-2 INFECTION (COVID-19) | MYLAN LABORATORIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000618-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | PRNP, F7, F5 | KLK5 753/4885NPY2R 2912/4885PRLHR 3314/4885 |
| US-20230149361-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS USING ANGIOTENSIN-CONVERTING ENZYME 2 INHIBITORS | ACE2, ACE, AGT | KLK5 175/4885NPY2R 605/4885PRLHR 1618/4885 |
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | KLK5 428/4885NPY2R 3175/4885PRLHR 3810/4885 |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | KLK5 1937/4885NPY2R 4579/4885PRLHR 4555/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | KLK5 428/4885NPY2R 3175/4885PRLHR 3810/4885 |
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | KLK5 432/4885NPY2R 3130/4885PRLHR 3804/4885 |
| US-20260053741-A1 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | ACE2, FURIN, PRSS2 | KLK5 1187/4885NPY2R 877/4885PRLHR 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.